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biomaterial is often necessary for adequate 
tissue regeneration.[3] Specific to bone, the 
therapeutic biomaterial should have osteo-
promotive characteristics, which facilitate 
the differentiation of undifferentiated cells 
in mature osteoblasts.[4] In turn, osteoblasts 
are a terminally differentiated form of pre-
osteoblasts (pre-Obs) and are responsible 
for bone formation by sequentially pro-
ducing bone matrix proteins, which sub-
sequently induce tissue mineralization.[5,6]
Layered double hydroxides (LDHs) can 
be described as a class of inorganic mate-
rials 2D organized with anion exchange 
properties and an interesting equilibrium 
between chemical stability and biodeg-
radability. A synthetic LDH with com-
position [Mg6Al2(OH)16]CO3∙4H2O, and 
known as hydrotalcite, is used commer-
cially as the antacid Talcid.[7] In the 1990s, 
several papers showed the efficacy of 
Talcid compared to other antacids already 
well known in the market through in 
vitro and in vivo tests.[8–10] These studies 
showed the efficacy of hydrotalcite in the 
gastric mucosal protection, angiogenesis 
activation of wounded mucosa, healing 
of gastroduodenal ulcers, and progress in 
the aspect of mucosal scar. In addition to its acid neutralization 
effect, Talcid can activate genes for epidermal growth factor as 
well as its receptor in normal and ulcerated gastric mucosa.
LDHs exhibit the [MII(1−x)MIIIx(OH)2]x+(Am−)x/m.nH2O gen-
eral formula where MII and MIII are di- and trivalent cations 
The effect of LDH samples comprised of chloride anions intercalated between 
positive layers of magnesium/aluminum (Mg-Al LDH) or zinc/aluminum 
(Zn-Al LDH) chemical composition on pre-osteoblast performance is investi-
gated. Non-cytotoxic concentrations of both LDHs modulated pre-osteoblast 
adhesion by triggering cytoskeleton rearrangement dependent on recruiting 
of Cofilin, which is modulated by the inhibition of the Protein Phosphatase 2A 
(PP2A), culminating in osteoblast differentiation with a significant increase of 
osteogenic marker genes. The alkaline phosphatase (ALP) and bone sialo-
protein (BSP) are significantly up-modulated by both LDHs; however, Mg-Al 
LDH nanomaterial promoted even more significance than both experimental 
controls, while the phosphorylations of mitogen-activated protein kinase 
(MAPKs)- extracellular signal–regulated kinases (ERK) and c-Jun N-terminal 
kinase (JNK) significantly increased. MAPK signaling is necessary to activate 
Runt-related transcription factor 2 (RUNX2) gene. Concomitantly, it is also 
investigated whether challenged osteoblasts are able to modulate osteoclas-
togenesis by investigating both osteoprotegerin (OPG) and Receptor activator 
of nuclear factor kappa-ligand (RANKL) in this model; a dynamic reprogram-
ming of both these genes is found, suggesting LDHs in modulating osteo-
clastogenesis. These results suggest that LDHs interfere in bone remodeling, 
and they can be considered as nanomaterials in graft-based bone healing or 
drug-delivery materials for bone disorders.
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1. Introduction
Bone defects are one of the most pressing problems in the 
medical–dental area.[1,2] Reconstruction of injured tissue is one 
of the greatest challenges for surgeons, and application of a 
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positioned in octahedral [M(OH)6] units share edges in an lay-
ered fashion (Figure 1a), while A represents an anion of valence 
m that is sandwiched between the layers, neutralizing their 
electrical positive charges (simplified notation is MIIRMIII–A, 
where R is the MII/MIII molar ratio).[11] Usually, the interlayer 
spaces and the external surfaces of LDHs are occupied by water 
molecules. The distance between the stacking layers can be 
modified to accommodate anions of different sizes, electrical 
charges, and chemical nature (inorganic or organic).
Considering the possibility of controlling the chemical 
composition of LDH layers and their affinity for anions, 
drugs, and other biological bioactive species, they have been 
confined between the inorganic layers for drug delivery and 
imaging.[12–15] Our group has been studying experimental 
parameters for the intercalation of drugs such as pravas-
tatin[16] and sulindac into LDHs and applying structural, spec-
troscopic, textural, and thermal techniques for their detailed 
characterization.[17,18] We recently reported the biological prop-
erties of a LDHs intercalated with the anion of mefenamic acid 
evaluated through the in vitro cytotoxicity tests by hemolysis, 
and in vivo tests concerning the anti-inflammatory activity 
and nociceptive effect of the intercalated and nonintercalated 
drug.[19] The mefenamate confinement in the LDH structure 
decreased its hemolytic effect and potentiated its anti-inflam-
matory and analgesic effects. In another study, the biocompat-
ibility of LDH containing magnesium and zinc as divalent as 
aluminum as trivalent metal (chloride as intercalated anion) 
was investigated by histology and microcirculatory dynamic 
imaging, through sidestream dark field imaging, after 
implantation into the abdominal wall of rats.[20] Remarkable 
biocompatibility, rapid induction of fibroblast proliferation, 
neovascularization, and subsequent collagen production in 
vivo assays were observed.
Studies focusing on the action of LDHs on bone cells are 
very scarce.[21,22] Hence, we investigated the effect of LDH 
materials on preosteoblast metabolism, mainly addressing 
their possibility to modulate the expression of osteogenic dif-
ferentiation genes. Summarizing, our results showed that both 
LDHs assayed here were able to modulate osteoblast metabo-
lism, further compromising osteoclastogenesis. Importantly, 
we report for the first time, the acquisition of osteogenic 
phenotype by LDHs in a mitogen-activated protein kinase 
(MAPK)-dependent manner. Thus, these results suggest LDHs 
as very interesting nanomaterials to be explored in bone bio-
engineering as a scaffold or drug-delivery materials for bone 
disorders.
2. Results
LDH samples were prepared and characterized as previ-
ously described.[12] According to data analysis, the chemical 
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Figure 1. Schematic representation of LDH structures and their cytotoxicity. a) Each octahedral unit has six hydroxide ions coordinated to the metal 
cation in the central site; each hydroxide ion is shared by three octahedrons (or three metal ions). The layers are in [ab] plane while assembling of the 
layers is accomplished in the c axis direction. To investigate the cytotoxic effect of LDHs, pre-Obs were plated and in the semiconfluence were subjected 
with different concentrations of LDHs, as shown. Pre-Obs were treated with conventional medium for the control group; b) Mg–Al LDH diluted in 
three different concentrations (0.002; 0.02; 0.2 mg) and c) Zn–Al LDH diluted in three different concentrations (0.002; 0.02; 0.2 mg). *p < 0.05; ***p < 
0.0002; ****p < 0.0001: Significant statistical difference when compared to control; #p < 0.05; ####p < 0.0001: Significant statistical difference when 
comparing Mg2Al–Cl 0.2 mg and Mg2Al–Cl 0.02–0.002 mg.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1700693 (3 of 12)
www.advancedsciencenews.com www.advhealthmat.de
formulae [Mg2.10Al(OH)6.20]Cl∙2.3H2O and [Zn2.08Al(OH)6.16]
Cl∙1.7H2O (abbreviated Mg2Al–Cl and Zn2Al–Cl) were pro-
posed. Zeta potential measurements of the LDH suspensions 
in water gave the values +41.7 mV for Mg2Al–Cl and +46 mV 
for Zn2Al–Cl.
Thereafter, both LDH samples were diluted in cell culture 
medium (0.002, 0.02, and 0.2 mg mL−1) to treat preosteoblasts 
in vitro to determine their cytotoxicity. After 24 h of treat-
ment, the cell viability test was performed by 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduc-
tion (vital dye able to be reduced by mitochondrial dehydroge-
nases). This showed that cell viability decreased around 20% 
compared to control when the concentration of both LDHs 
was 0.2 mg mL−1 (Figure 1b,c). However, at 0.002 mg mL−1, 
both LDHs did not present any cytotoxicity, but Mg2Al–Cl 
promoted a significant increase of dehydrogenase activities 
(Figure 1b).
2.1. LDH Materials Affect Preosteoblast Adhesion  
by Modulating Cofilin and PP2A Phosphorylations
To evaluate the first effect of LDH on pre-Ob adhesion, the 
cells were subjected to both LDHs separately up to 24 h, then 
the cells were trypsinized, counted, and replated. After 3 and 
24 h, the adherent cells were stained with violet crystal, which 
allowed us to estimate cell adhesion in response to LDH 
(Figure 2a,b). After the first 3 h of adhesion, LDH containing 
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Figure 2. LDH impacts pre-Ob adhesion by modulating Cofilin/PP2A balance. Pre-Ob maintained with conventional medium was the control group. 
a,b) First, cell adhesion was measured by vital violet crystal after 3 and 24 h of plating, where treatments were made at a concentration of 0.002 mg mL−1, 
as suggested previously as a subtoxic concentration. Thereafter, immunoblots showed the profile of phosphorylation of cofilin and PP2A, and Rac-1 
expression. Representative results are depicted and the graphs represent arbitrary values obtained by a densitometric analysis of bands normalized 
by the mean values of the respective GADPH (internal control) bands. c,d) Expression analysis of Rac1; e,f) analysis of p-Cofilin/Cofilin ratio; and 
g,h) analysis of the expression of p-PP2A/PP2A ratio. Statistical significances were considered when: **p < 0.0017; ***p < 0.0002; ****p <0.0001:. 
#p < 0.05; ####p < 0.0001. Statistical significances were considered when comparing Mg2Al–Cl 0.2 mg and Mg2Al–Cl 0.02–0.002 mg. (a) p < 0.05: Sig-
nificant statistical difference when comparing Mg2Al–Cl 3 h and Zn2Al–Cl 3 h. (b) p < 0.05: Significant statistical difference when comparing Mg2Al–Cl 
24 h and Zn2Al–Cl 24 h. (c) Significant statistical difference when comparing Mg2Al–Cl 3 h and Mg2Al–Cl 24 h. (d) p < 0.0017: Significant statistical 
difference when comparing Zn2Al–Cl 3 h and Zn2Al–Cl 24 h. (e) p < 0.0002: Significant statistical difference when comparing Mg2Al–Cl 3 h and Zn2Al–Cl 
24 h. (f) Significant statistical difference when comparing Zn2Al–Cl 3 h and Mg2Al–Cl 24 h.
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Zn2+ (Zn2Al–Cl) significantly upmodulated pre-Ob adhesion, 
while cells treated with Mg2+ (Mg2Al–Cl) remained unchanged. 
After 24 h, the same procedure was carried out, and LDHs pro-
duced an inverse effect; Mg2Al–Cl upmodulated pre-Ob adhe-
sion, Zn2Al–Cl downmodulated it (Figure 2a,b).
Later, we investigated how the molecular machinery was 
involved during pre-Ob adhesion at 3 and 24 h, mainly with 
regard to the signaling protein involved with cytoskeleton rear-
rangement, which was previously proposed to be a pre-Ob adhe-
sion biomarker.[23–25] Our results found that Rac-1 decreased in 
response to both evaluated LDHs at both chosen experimental 
times (Figure 2c,d).
Additionally, the phosphorylation of Cofilin significantly 
increased in response to both LDHs, with very similar phos-
phorylation profile at both 3 and 24 h (Figure 2e,f). Zn2Al–Cl 
produced a more significant response, which was greater at 
3 h than at 24 h (Figure 2e,f). The Mg-doped LDHs produced 
a similar response at both 3 and 24 h, which were significantly 
different than control (Figure 2e,f).
Finally, we investigated the involvement of PP2A, a very 
important Ser/Thr phosphatase able to modulate Cofilin 
phosphorylation balance by hydrolyzing the phosphoryl moiety 
from the phosphorylated protein, during pre-Ob adhesion. The 
phosphorylation of PP2A was assayed at Y307, a well-known 
inhibitory phosphorylation site of PP2A. Our results showed 
that the phospho-PP2A/PP2A ratio was decreased at 3 h of cell 
adhesion in response to both the LDHs assayed (Figure 2g,h). 
However, at 24 h, it was significantly increased in response to 
Zn2Al–Cl (Figure 2g,h).
2.2. LDH Materials Require MAPK Activations during 
Osteogenic Pathway
Next, we focused on the possibility that LDHs promote pre-Ob 
differentiation. We experimentally treated pre-Ob with both 
the LDH nanohybrids, separately up to 14 d, when it was pos-
sible to determine the osteogenic phenotype, as detailed else-
where. After 14 d, biological samples were collected and used 
for different technologies. First, we focused on understanding 
whether AKT and MAPKs are required in response to LDHs. 
MAPKs in osteoblasts are critical transducers able to main-
tain bone mass.[26] Our result clearly showed that phospho-
rylation of AKT was downregulated, but required, in response 
to both LDH materials (Figure 3a,b). The very similar profile 
was also seen in response to the positive control, where the 
cells were treated with osteogenic medium. Importantly, both 
MAPKs p44/p42 extracellular signal-regulated kinase (ERK) 
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Figure 3. LDHs promote osteoblastic differentiation by upactivating both MAPKs – ERK and JNK. Pre-Obs were plated and at semiconfluence were 
treated with different experimental condition, as follows: control group, osteogenic medium (O.M.), Mg2Al–Cl, and Zn2Al–Cl. After 14 d of treatment, 
the cells were scraped then lysed using standard lysing buffer (as described in detail in the Experimental Section), and the pooled protein was resolved 
on SDS-PAGE gel. After polyvinylidene difluoride (PVDF) membrane transferring, cells were incubated using specific primary antibody in western blot-
ting technology. The proteins investigated were: a,b) AKT; MAPKs c,d) ERK and e,f) JNK. Representative blottings are shown, and the graphs represent 
arbitrary values obtained by densitometric analysis of bands normalized by the average values of the respective GADPH bands (housekeeping control). 
*p < 0.05; **p < 0.015; ****p < 0.0001: Significant statistical difference when compared to control.
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(Figure 3c,d) and c-jun N-terminal kinase (JNK) (Figure 3e,f) 
were significantly upmodulated in response to both the LDH 
samples.
2.3. LDH-Induced Extracellular Matrix (ECM) Remodeling 
Requires Dynamic Matrix Metalloproteinases (MMPs) and Their 
Inhibitor Gene Reprograming
Additionally, we focused on understanding whether the 
ECM remodeling mechanism was modulated by LDH. We 
stained ECM cells with three different protocols to verify the 
behavior of the cells and in vitro-secreted extracellular matrix. 
Hematoxylin & eosin staining suggests a loose connective 
tissue in response to both LDH samples (Figure 4a), which 
was validated by Picrosirius red staining (Figure 4a,b). At 
this point, there was a significant staining on collagen fibers 
in response to both LDHs (Figure 4b), which was lower in 
response to Mg–Al LDH.
These results prompted us to investigate whether ECM 
remodeling-related genes were involved, and we found dynamic 
gene reprograming in response to both LDHs (Figure 4). ECM 
serves diverse functions and is a major component of the cel-
lular microenvironment,[27] and its remodeling is mainly gov-
erned by MMPs and their tissue inhibitors (tissue inhibitors 
of matrix metalloproteinases (TIMPs) and reversion-inducing-
cysteine-rich protein with kazal motifs (RECK)). Thus, it is 
reasonable to suggest the modulation of MMPs, TIMPs, and 
RECK in response to LDHs, because they are involved with the 
development of mineralized tissue.[28–30] Mg–Al LDH promoted 
a significant upexpression of MMP9 and TIMP1, while MMP2, 
TIMP2, and RECK remained very similar to the control group 
(Figure 4c–g). With Zn–Al LDH, there was significant upactiva-
tion of MMP2, while all those MMP-related inhibitors evaluated 
here were upmodulated (Figure 4c–g). Differential modulation 
of ECM remodeling-related genes occurred with both LDHs, 
which suggests lower activity of MMPs in response to Zn–Al 
LDH, as all MMP inhibitors were upexpressed, impairing MMP 
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Figure 4. LDHs promote ECM remodeling during osteoblast differentiation. We evaluated ECM remodeling by first staining the cells with a) hema-
toxylin & eosin and b) collagen fibers (Picro siruis). As ECM-remodeling seemed to be modulated by LDHs, we investigated whether MMPs and their 
inhibitors were required in response to LDHs. The cells were cultured up to 14 d, when the total mRNA was collected and forwarded to quantitative 
polymerase chain reaction (qPCR) technology. ECM remodeling-related genes were investigated as follows: c) MMP2, d) MMP9, e) TIMP1, f) TIMP2, 
and g) RECK. The ECM-related genes clearly reprogramed in response to both LDHs. *p < 0.05; **p < 0.015; ***p < 0.0002; ****p < 0.0001: Significant 
statistical difference when compared to control.
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activities. Thus, this balance of ECM-related gene reprograming 
may explain the difference of collagen I content response to 
both LDHs (Figure 4b).
2.4. Both LDH Materials Promoted Expression of Osteogenic 
Marker Genes
To evaluate osteogenic phenotype, we first found that both 
evaluated LDH materials could trigger intracellular pathways 
culminating in osteogenic markers of gene expressions. Both 
LDH samples promoted a significant increase of RUNX2 when 
compared to immediate control, where the cells were cultured 
at classical condition, and to the positive control (Figure 5a), 
where the cells were incubated with an osteogenic medium (see 
the Experimental Section for details). In addition, both LDHs 
upmodulated Osterix expression, when compared to imme-
diate control (Figure 5b), but only Mg2Al–Cl material promoted 
a very significant increase, when compared to both listed con-
trols. Similar to RUNX2 and Osterix, Osteocalcin mRNA was 
also significantly upexpressed (Figure 5d). Importantly, alka-
line phosphatase (ALP mRNA) was significantly upmodulated, 
reaching almost 50-fold increase compared to unchallenged 
cells (Figure 5c). This result was validated by ALP staining 
(Figure 5i). In addition, Osteopontin (OPN mRNA), bone sialo-
protein (BSP mRNA), bone morphogenetic proteins (BMP2), 
and BMP7 genes were investigated. OPN mRNA was signifi-
cantly upmodulated in response to Zn–Al LDH (sixfold changes 
increase) (Figure 5e). Importantly, BSP mRNA emerged as the 
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Figure 5. LDHs promote osteoblast differentiation. To evaluate the impact of LDH on osteoblast differentiation, we have added another control group, 
where the cells were maintained under a classical osteogenic medium treatment [β-Glycerophosphate (10 × 10−3 m) + Dexamethasone (0.03 g mL−1) + 
ascorbic acid (50 µg mL−1)]. The cells were cultured in each experimental condition up to 14 d; then the samples were extracted, cDNA synthesis 
processed, the expressions of osteogenic markers genes evaluated. a) RUNX2 upmodulation in response to LDHs, as well as b) Osterix, c) ALP, and 
d) Osteocalcin. Additionally, e) Osteopontin (OPN) and f) bone sialoprotein (BSP) upmodulated in response to LDHs. Curiously, BSP had almost 
50-fold greater changes compared to unchallenged cells. In addition, we also investigated whether the BMP-induced autocrine signaling was required 
by analyzing the activation of g) BMP2 and h) BMP7 genes. Complementarily, we subjected challenged cells to ALP staining to elucidate i) the dis-
tribution of this enzyme and j) mineralization in vitro by Alizarin S Red. *p < 0.05; **p < 0.015; ***p < 0.0002; ****p < 0.0001: Significant statistical 
difference when compared to control.
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only bona fide candidate for hydroxyapatite nucleation,[31] and 
this gene considerably increased in response to LDHs (greater 
than 40-fold increase for both LDHs) (Figure 5f). Both BMP 
genes presented very similar profile for both LDHs, which 
was higher in response to Zn–Al LDH (Figure 5g,h). Curi-
ously, both BMP2 and BMP7 mRNAs were downregulated in 
response to osteogenic medium and Mg–Al LDH, suggesting 
that there is no a autocrine BMP-induced stimulation of osteo-
blast differentiation (Figure 5g,h).
In addition, we stained the cells with Alizarin S red to esti-
mate the in vitro mineralization. Our results showed that both 
LDH materials promoted in vitro mineralization similar to the 
positive control (Figure 5j). This result reinforces the activity of 
BSP as a mineralizing nucleation protein (Figure 5f).
2.5. LDH Promotes Upexpression of Receptor Activator of 
NF-KappaB Ligand (RANKL) and osteoprotegerin (OPG), Which 
Probably Interfere in Osteoclastogenesis
Hematopoietic cell-derived osteoclasts depend on osteoblast 
metabolism, largely because osteoblasts express the RANKL, 
which is an essential cytokine for osteoclastogenesis. On the 
other hand, osteoblasts also produce OPG, a decoy receptor 
for RANKL, which inhibits osteoclast differentiation. Thus, 
the RANKL/RANK/OPG balance is a central axis to modulate 
osteoclastogenesis.[32] Thus, we are interested whether LDH-
challenged osteoblast can modulate both OPG and RANKL 
genes. Our results found a dynamic reprograming of both OPG 
mRNA and RANKL mRNA in response to both LDHs. Both 
Mg–Al LDH and Zn–Al LDH promoted a considerable increase 
on OPG expression (Figure 6a), which was highest in response 
to Zn–Al LDH, when compared to control group (Figure 6a). In 
turn, RANKL mRNA was also modulated in response to both 
LDHs, but only Zn–Al LDH promoted a higher expression than 
other groups (Figure 6b). Importantly, the chemical-induced 
osteoblast differentiation by osteogenic medium (here used as 
a positive control of the osteogenic phenotype) does not seem 
to contribute to osteoclatogenesis, since both OPG mRNA and 
RANKL mRNA were downregulated compared to unchallenged 
osteoblasts (Figure 6a,b). Figure 6c illustrates the effect of LDH 
on osteoclastogenesis which stimulates osteoblast upregulation 
of RANKL and OPG.
Summarizing, Figure 7 illustrates the signaling pathways 
involved in response to LDH by osteoblasts. LDH promotes 
osteoblastic phenotype by upregulating osteogenic marker 
genes. In addition, we reported that LDH is an important stim-
ulus for osteoclastogenesis, due to upregulation of OPG and 
RANKL expressions. Thus, LDH should be considered in bone 
disorders.
Adv. Healthcare Mater. 2018, 7, 1700693
Figure 6. LDHs contribute in osteoblast-induced osteoclastogenesis. LDH-challenged osteoblasts were lysed and the total mRNA collected. After 
cDNA synthesis processing, the expressions of RANKL and OPG genes were evaluated. Both LDHs promoted upexpression of a) OPG, while RANKL 
was upexpressed only in response to b) Zn–Al LDH. c) RANKL and OPG are proteins released by osteoblast and related with osteoclastogenesis. **p < 
0.015; ****p < 0.0001: Significant statistical difference when compared to control.
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3. Discussion
Novel strategies need to be investigated to clinically regen-
erate bone when there are critical-sized bone defects. Materials 
able to repair bone by stimulating an expression of marker 
genes in osteogenic differentiation are urgently necessary. We 
addressed this by investigating the effects of LDHs on pre-Ob 
performance. Immediately after their synthesis and characteri-
zation, the LDHs were used to challenge pre-Ob to verify their 
cytotoxicity, as recommended by ISO 10993-5:2016.
After identifying a safe concentration, we intensified the 
experiments for possible use in bone scaffold or drug-delivery 
nanomaterial for bone disorders. In sequence, we showed 
that LDH interferes pre-Ob adhesion by modulating a crucial 
intracellular pathway involved with cytoskeleton rearrange-
ment, because important transducers as Rac-1, Cofilin, and 
PP2A were dynamically modulated. Rac-1 protein decreased 
in response to both evaluated LDHs, while phosphorylation of 
Cofilin significantly increased in response to both LDHs, pre-
senting a very similar phosphorylation profile at both 3 and 
24 h. This phosphorylation balance of Cofilin can be explained 
by the strong inactivation of PP2A,[25,33,34] because this Ser/Thr 
phosphatase was significantly phosphorylated in response to 
both LDHs. It is very known that PP2A modulates cytoskeleton 
rearrangement by guiding Cofilin phosphorylation at 
Serine 03.[35] Elsewhere, we reported that intracellular pathways 
culminating in cytoskeleton rearrangement are very important 
to guarantee pre-Ob morphological changes in the beginning of 
the interaction with the substrate.[36]
After favoring cell adhesion, the promising novel candidates 
for application in bone disorders need to stimulate the differen-
tiation of pre-Ob into mature osteoblasts. Thus, we investigated 
if LDH promoted osteoblast differentiation by upmodulating 
classical marker genes, such as the expression of early marker 
genes for osteoblast differentiation like RUNX2 and Osterix 
(OSX) as late marker gene, osteocalcin (OCN). Our results 
found that both LDH materials promoted a significant increase 
of RUNX2 and OCN when compared to the experimental con-
trols. OSX mRNA was also upmodulated by the both LDHs, but 
Mg2Al–Cl was more significant compared to the both experi-
mental controls. During the molecular sequence of bone for-
mation, OSX is essential for osteoblast differentiation and 
intramembranous/endochondral bone formation,[37,38] while 
RUNX2 is a bone-requisite transcription factor for the matu-
ration of osteoblasts, whereas OSX is a downstream gene of 
RUNX2.[39–42] Interestingly, Baek et al.[43] reported that in OSX-
inactivated adult mice, RUNX2 expression was significantly 
increased. Although the exact mechanism is not yet clear, they 
suggested that the increased RUNX2 expression may be partly 
caused by the lack of OSX-mediated negative feedback mecha-
nism and its expression may be controlled by the activation of 
the OSX-mediated gene. Therefore, it is reasonable to purpose 
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Figure 7. Schematic representation of the LDH-based intracellular signaling. LDHs promoted profound intracellular consequences on preosteoblast 
(pre-Ob) metabolism interfering in bone remodeling. First, LDHs promoted a significant modulation of cytoskeleton-related proteins, culminating in 
pre-Ob adhesion up to 24 h as a prerequisite for osteoblast differentiation. In addition, LDHs promote osteogenic phenotype at a MAPK-dependent 
signaling. As consequences, LDHs promote a dynamic ECM reprograming of remodeling-related genes and also contribute to osteoclastogenesis, 
since they upmodulate both RANKL and OPG in challenged osteoblast. The balance of RANKL and OPG orchestrates the fusion of mononuclear cells, 
culminating in specialized multinucleated osteoclasts that are responsible for promoting bone resorption. Summarizing, our data showed that LDH 
has an important effect on bone remodeling because it interferes with osteoblast and osteoclast.
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that Zn2Al–Cl LDH interfered with the pre-Ob differentiation 
by a similar mechanism, as the RUNX2 mRNA was signifi-
cantly upexpressed (almost threefold changes compared to con-
trol) while OSX mRNA was moderately expressed. As reported, 
bone matrix mineralization is widely regulated by the sequential 
marker gene expressions, which strictly depends on the stage 
of osteoblast differentiation. In addition, we subjected the cell 
to different staining to identify a profile of collagen deposition 
and late in vitro mineralization by performing Picrosirus and 
Alizarin S red, respectively. As previously noticed elsewhere, we 
found a difference in the collagen deposition and mineraliza-
tion distinguishing both LDHs evaluated in a descriptive and 
qualitative way. However, other methodologies must be applied 
for more conclusive explanations of this matter (e.g., members 
of collagen family and BSP expressions by qPCR).
Additionally, investigation of intracellular pathways showed 
that MAPKs ERK and JNK were required in response to both 
LDHs, while AKT remained active. It is well-known that MAPK 
superfamily, including ERKs and JNKs, integrates signals 
from a wide range of extracellular stimuli, guiding important 
roles in cellular fate such as proliferation, differentiation, and 
cell death. For bone, Kim et al.[44] indicated that osteoblast dif-
ferentiation requires activating ERK and JNK, elucidating the 
molecular basis of the osteogenic effects of Fucoidan in mes-
enchyme stem cells; however, the JNK–MAPK pathway is by far 
the least understood MAPK pathway in osteoblasts, because the 
bone phenotype of JNK-deficient mice has yet to be reported.[26] 
The elegant work by Matsuguchi et al.[45] strongly suggests a 
critical role of JNK in the process of osteoblast differentiation.
MAPKs regulate key transcriptional mediators of osteoblast 
differentiation, with ERK and p38 MAPKs phosphorylating 
RUNX2, the master regulator of osteoblast differentiation.[26] 
The domains involved in ERK binding to RUNX2 have been 
mapped to a MAPK-binding D-domain, which is the C-terminal 
proline/serine/threonine-rich domain of RUNX2,[46,47] indi-
cating that ERK activity may be differentially regulated in the 
context of specific osteoblast-relevant promoters. Further work 
is needed to identify both the range of genes bound by ERK and 
the functional importance of this association, as suggested by 
Greenblatt et al..[26]
We showed for the first time that both LDH Mg2Al–Cl and 
Zn2Al–Cl promoted osteoblast differentiation by upmodulating 
osteoblastic classical marker genes (RUNX2, OSX, and OCN) by 
requiring the activation of JNK and ERK, while AKT remained 
in an active status. Additionally, because adequate osteoblastic 
differentiation is essential to maintain bone mass through life 
and strictly necessary for bone healing, LDHs must be explored 
as therapeutic nanomaterials to be applied into bone disor-
ders as a scaffold for bone bioengineering or as a drug-delivery 
material to release topically specific molecules that facilitate 
local bone repair.
4. Experimental Section
Reagents: The antibodies used include Rac1/Cdc42 Antibody (#4651, 
21 kDa); Cofilin (D59) Antibody (#3318, 19 kDa); Phospho-Cofilin (Ser3) 
Antibody (#3311, 19 kDa); glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (14C10) Rabbit mAb (#2118, 37 kDa); AKT Antibody (#9272, 
69 kDa); ERK (42, 44 kDa), p-ERK (42, 44 kDa); AKT (#4685, 60 kDa); 
Phospho-AKT (#4060, 60 kDa)), and JNK (46, 54 kDa) (Phospho-MAPK 
Family Antibody Sampler Kit #9910). Anti-PP2A alpha + beta antibody 
(ab137849) was purchased from Abcam (Cambridge, MA, USA) and 
Anti-PP2A alpha + beta antibody [phospho-Y119] from Cell Signaling 
(Danvers, MA, USA). All the other chemicals and reagents used in this 
study were of analytical grade, purchased from commercial sources.
Cell Culture and Conditions: Preosteoblasts were plated on cell-
culture dish plates with a density of 25 000 cells cm−2 and cultured 
in minimum essential medium eagle-α modification (α-MEM) until 
they were confluent. The cells were maintained in osteogenic medium 
(100 U mL−1 penicillin, 100 mg mL−1 streptomycin), supplemented 
with ribonucleosides and deoxyribonucleosides with the addition of 
β-glycerophosphate (10 × 10−3 m) and ascorbic acid (50 µg mL−1) for 
αMEM (considered osteogenic medium, O.M.). Cells were cultured 
for 14 d, with the medium changed every 3 d. Cells were maintained at 
37 °C, 5% CO2, and 95% humidity.
Cell Viability Was Measured by MTT Reduction: Briefly, cells 
(25 000 cells cm−2) were plated 48 h prior to treatment in a 96-well plate. 
After 24 h of plating, they were exposed to different concentrations of 
both LDHs up to 24 h, then the cell viability was assessed by the MTT 
approach. The cell culture medium was removed, and immediately 
MTT (1 mg mL−1) was added, and they were kept in an incubator for 
an additional 4 h. Then, the medium containing MTT was removed and 
1 mL of dimethyl sulfoxide was added for solubilization of the blue dye 
formed by viable cells.[48] Afterward, the absorbance was measured at 
570 nm using a microplate reader (SYNERGY-HTX multi-mode reader, 
Biotek, USA).
Cell Adhesion Was Assayed by Violet Crystal: For the adhesion approach, 
MC3T3-E1 cells were treated properly with the both LDH samples up 
to 24 h. Then, the cells were trypsinized, resuspended in conventional 
medium containing LDH, counted in hematological chamber, and plated 
(25 000 cells cm−2) in 96-well plates.[49] After plating, cell adhesion was 
estimated by incorporation of crystal violet dye at the 3 h and 24 h 
postplating times.
Western Blotting: Respecting the different proposals, after 3 and 24 h 
for adhesion and 14 d for differentiation, the cells were lysed with Lysis 
buffer (50 × 10−3 mol L−1, Tris-HCl, pH 7.4, 1% Tween 20, 0.25% sodium 
deoxycholate, 150 × 10−3 mol L−1 NaCl, 1 × 10−3 mol L−1 ethylene glycol 
tetraacetic acid (EGTA), 1 × 10−3 mol L−1 O-Vanadate, 1 × 10−3 mol L−1 
NaF, and protease inhibitors 10 µg mL−1 leupeptin and 1 × 10−3 mol L−1 
4-aminoethyl fluorosulfonyl 4-hydrochloride hydrochloride). The samples 
were sonicated (1 pulse s−1, in a SONICS Vibra-Cell equipment) and 
maintained for 1 h on ice, when in each sequential 20 min, the samples 
were vortexed. Then, protein extracts were pooled by centrifuging 
(14 000 rpm) and the protein amount determined by the Lowry 
method.[50] Finally, the protein extracts were added of 2× Laemmli buffer 
[2× sodium dodecyl sulfate (SDS), 100 × 10−3 mol L−1 Tris-HCl [pH 6.8], 
200 × 10−3 mol L−1 dithiothreitol (DTT), 4% SDS, 0.1% bromophenol 
blue, and 20% glycerol], and maintained for 5 min at 95 °C. Once 
prepared, the samples were resolved on sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel.
Osteogenic Phenotype: The osteogenic classical marker genes were 
analyzed by qPCR. For expression analysis, TriZol was added to the 
cultures and pelleted. After centrifugation, addition of chloroform and 
centrifugation, DNA, RNA, and protein phases were formed in the tube. 
RNA samples were quantified using plate reader (SYNERGY-HTX multi-
mode reader, Biotek, USA). The next step was cDNA synthesis using the 
High-Capacity cDNA Reverse Transcription Kit – Applied Biosystems 
[2.0 µL of 10× RT Buffer, 0.8 µL 25× dNTP Mix (100 × 10−3 mol L−1), 
2.0 µL 10× RT Randon Primers, 1.0 µL MultiScrible Reverse Transcriptase, 
4.2 µL Nuclease-Free H2O], then 200 ng µL−1 of each sample was added 
for cDNA synthesis in a 96-well plate and taken to the QuantStudio 
3 (Applied Biosystems). After this initial process, the material was 
collected and evaluated for the expression (Table 1). In addition, 
histochemical staining for ALP activity in the cells was determined using 
Sigma Fast BCIP/NBT Tablets (B5655) according to the manuals.
In Vitro Picrosirius Staining: Preosteoblasts were plated at a density 
of 8 × 104 cells mL−1 in 24-well plates and in semiconfluence treated 
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with the different LDH materials up to 14 d. For qualitative analysis of 
collagen content, the cells were washed in phosphate buffered saline 
(PBS) and fixed in 4% paraformaldehyde for 1 h and then stained for 
90 min in a 0.1% solution of red Sirius in saturated aqueous picric 
acid, pH 2. Next, the cells were washed for 2 min in 0.01 n HCl and 
counterstained with Harris Hematoxylin for 6 min, washed in ethanol 
70%, dehydrated, and mounted using Permount. For the conventional 
fluorescence microscope, images were acquired in the inverted 
microscope Axio Vert.A1 (Zeiss, Germany).
In Vitro Hematoxylin & Eosin Staining: Preosteoblasts were plated at 
a density of 8 × 104 cells mL−1 in 24-well plates and in semiconfluence 
treated with the different LDH materials up to 14 d. For a morphological 
analysis of the cells, hematoxylin & eosin technology was used, 
where the cells were previously fixed in phosphate-buffered 4% 
paraformoldehyde for 40 min, washed with water for 7 min, incubated 
for 5 min in hematoxylin, washed with water for 3 min, and stained with 
eosin for 7 min. Then, the coverslips were dehydrated and photographed 
under a conventional optical microscope Axio Vert.A1 (Zeiss, Germany).
In Vitro Alizarin S Red Staining: Preosteoblasts were plated at a density 
of 8 × 104 cells mL−1 in 24-well plates and in semiconfluence treated with 
the different LDH materials, as previously described, up to 14 d. The 
medium was changed every 3 d. In vitro mineralization was measured 
during osteoblast differentiation process by alizarin Red S staining. 
The culture medium was gently removed and washed with warm PBS. 
Table 1. Expression primer sequences and PCR cycle conditions.
Gene Primer 5′–3′ Sequence Reaction condition
MMP2 Forward AACTTTGAGAAGGATGGCAAGT 95 °C – 3 s; 60 °C – 8 s; 72 °C – 20 s
Reverse TGCCACCCATGGTAAACAA
MMP9 Forward TGTGCCCTGGAACTCACACGAC 95 °C – 3 s; 62 °C – 8 s; 72 °C – 20 s
Reverse ACGTCGTCCACCTGGTTCACCT
TIMP1 Forward ATCCTCTTGTTGCTATCACTG 95 °C – 5 s; 60 °C – 10 s; 72 °C – 15 s
Reverse GGTCTCGTTGATTTCTGGG
TIMP2 Forward GCAACAGGCGTTTTGCAATG 95 °C – 3 s; 60 °C – 8 s; 72 °C – 20 s
Reverse CGGAATCCACCTCCTTCTCG
RECK Forward CCTCAGTGAGCACAGTTCAGA 95 °C – 3 s; 60 °C – 8 s; 72 °C – 20 s
Reverse CCTGTGGCATCCACGAAACT
Col 1A1 Forward ATGACGTGATCTGTGACGAGAC 95 °C – 3 s; 62 °C – 8 s; 72 °C – 20 s
Reverse TTCTTGGTCGGTGGGTGAC
Col 3A1 Forward GACCTGAAATTCTGCCATCC 95 °C – 3 s; 62 °C – 8 s; 72 °C – 20 s
Reverse GCATGTTTCCCCAGTTTCC
BSP Forward GTACCGGCCACGCTACTTTCT 95 °C – 3 s; 60 °C – 8 s; 72 °C – 20 s
Reverse GTTGACCGCCAGCTCGTTTT
BMP2 Forward GGTCACAGATAAGGCCATTGC 95 °C – 3 s; 60 °C – 8 s; 72 °C – 20 s
Reverse GCTTCCGCTGTTTGTGTTTG
BMP7 Forward TGACAAAGAATTCTTCCACCCTCGA 95 °C – 5 s; 72 °C – 10 s; 72 °C – 15 s
Reverse GTAATACGACTCACTATAGGGCAGGGTTGCTTGTTCTGGGGT
OPG Forward CAGAGACTAATAGATCAAAGGCAGG 95 °C – 3 s; 60 °C – 8 s; 72 °C – 20 s
Reverse ATGAAGTCTCACCTGAGAAGAACC
RANKL Forward CGCTCTGTTCCTGTACTTTCGAGCG 95 °C – 3 s; 60 °C – 8 s; 72 °C – 20 s
Reverse TCGTGCTCCCTCCTTTCATCAGGTT
RUNX2 Forward GGACGAGGCAAGAG 1 II CA 95 °C – 3 s; 55 °C – 8 s; 72 °C – 20 s
Reverse TGGTGCAGAGTTCAGGGAG
ALP Forward GAAGTCCGTGGGCATCGT 95 °C – 3 s; 55 °C – 8 s; 72 °C – 20 s
Reverse CAGTGCGGTTCCAGACATAG
Osteocalcin (OCN) Forward AGACTCCGGCGCTACCTT 95 °C – 3 s; 55 °C – 8 s; 72 °C – 20 s
Reverse CTCGTCACAAGCAGGGTTAAG
Osterix (OSX) Forward CCC TTC CCT CAC TCA TTT CC 95 °C – 5 s; 56 °C – 10 s; 72 °C – 15 s
Reverse CAA CCG CCT TGG GCT TAT
Osteopontin Forward TTTGCTTTTGCCTGTTTGGC 95 °C – 5 s; 60 °C – 10 s; 72 °C – 15 s
Reverse CAGTCACTTTCACCGGGAGG
β-actin Forward TCTTGGGTATGGAATCCTGTG 95 °C – 3 s; 55 °C – 8 s; 72 °C – 20 s
Reverse AGGTCTTTACGGATGTCAACG
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Thereafter, the PBS was removed, and 0.5 mL of 10% formalin was 
added for cell fixation. The plate was held in that solution for 30 min at 
room temperature. After this period, formalin was removed, and Alizarin 
solution (1%) added in the cultures, and then they were incubated in the 
dark chamber for additional 45 min. The cells were washed five times in 
PBS. Finally, cell images were acquired by using an inverted microscope 
(Zeiss, Germany).
Statistical Analysis: Results were plotted as mean ± standard 
deviation and verified using one-way analysis of variances (ANOVA) 
(nonparametric) with Tukey’s post-test, to compare all pairs of 
groups. In this case, p < 0.05 was considered statistically significant 
and p < 0.0001 considered highly significant. The software used was 
GraphPad Prism 6. For particle counting, ImageJ Software was used 
to determine the number of points in the area recorded in the photo, 
and for the statistical analysis, the groups were standardized by the 
percentage of the control.
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